Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components

Table 3 Cost of health resources used in the baseline model (in Euros, €)

Hospitalisation costs^a	DRG code	Cost
Condition
Hypertension	K37X	355
Angina	K47M	940
Post-Angina	K47X	424
Myocardial Infarction (MI)	K40M	1818
Post-MI	K32X	968
Stroke	N30Mβ	1625
Post-Stroke	N30Mβ	1625
CHF	Κ42Χ	849
Rehabilitation (Stroke)	S20Χ	2716
Death	-	1200
Intervention
PCI	Κ15Χ	1761
CABG	Κ05Χ	6495
Angiography	Κ32Α	498
Pacemaker	Κ12Χ	2831
ICD	Κ01Χ	11,291
CRT	-	7270
Heart Transplantation	Ε05Α	34,000
Clinical, Laboratory and Imaging Exam Costs^b		Cost
Outpatients Visits		10
Physiotherapists		20
CT Scans		71.11
MRI		236.95
MRA		235.00
Thallium Scintigraphy		260.00
Carotid Triplex		73.37
Echocardiography		70.00
Blood and Biochemistry Tests^c		57.40
Treadmill Stress Test		28.11

Abbreviations: CHF congestive heart failure, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, ICD implantable cardioverter-defibrillator, CRT cardiac resynchronisation therapy, CT computed tomography, MRI magnetic resonance imaging, MRA Magnetic Resonance Angiography
^aHospitalisation costs derive from the Government Gazette issued in March 2012 by the Ministry of Health; cost of death is extracted from Maniadakis et al. 2005 [37] and CRT cost is obtained from a Government Gazette published in 2007
^bClinical, laboratory and imagining examination costs are obtained from a Government Gazette that is valid in November, 2013
^cRoutine laboratory tests include blood count, urine test, test for levels of glucose, urea, creatinine, sodium, potassium, SGOT (serum glutamic-oxaloacetic transaminase), SGPT (serum glutamic-pyruvic transaminase), CPK (creatine phosphokinase), total cholesterol, HDL-C (high-density lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol), triglycerides, uric acid

ISSN: 1478-7547